Yellow Jersey Therapeutics

Yellow Jersey Therapeutics was acquired by Johnson & Johnson in 2024

Yellow Jersey Therapeutics was a wholly owned subsidiary of Numab Therapeutics, addressing unmet needs in atopic dermatitis. The agreement with Johnson & Johnson includes rights to NM26, a bi-specific antibody for the treatment of atopic dermatitis, for a purchase price of $1.25 billion in cash.

NM26 targets IL-4Rα (type I and type II receptors) and IL-31, to address the hallmarks of the pathophysiology of atopic dermatitis. The antibody was discovered and engineered, using Numab’s proprietary MATCH technology platform, which is designed to fuel a new wave of multi-specific antibody drug candidates.